Compare Stocks: SPRY, GHRS, ETON, and ANIP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$76.14 +1.0%	$76.18	$69.58 ▼ $98.04	$1.75B	0.45	368,306 shs	1.16 million shs
ETON Eton Pharmaceuticals	$55.50 -2.8%	$51.83	$14.27 ▼ $66.37	$1.59B	0.9	465,441 shs	891,649 shs
GHRS GH Research	$28.26 -1.6%	$28.32	$12.04 ▼ $31.44	$1.94B	1.27	173,673 shs	132,821 shs
SPRY ARS Pharmaceuticals	$4.11 -1.0%	$5.78	$4.10 ▼ $13.15	$408.73M	1.05	1.44 million shs	1.89 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	0.00%	+8.48%	-1.53%	-4.21%	-20.16%
ETON Eton Pharmaceuticals	0.00%	-2.77%	-7.36%	+70.87%	+213.91%
GHRS GH Research	0.00%	+3.90%	-1.46%	+27.07%	+126.08%
SPRY ARS Pharmaceuticals	0.00%	-13.66%	-25.41%	-57.41%	-57.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$76.14 +1.0%	$76.18	$69.58 ▼ $98.04	$1.75B	0.45	368,306 shs	1.16 million shs
ETON Eton Pharmaceuticals	$55.50 -2.8%	$51.83	$14.27 ▼ $66.37	$1.59B	0.9	465,441 shs	891,649 shs
GHRS GH Research	$28.26 -1.6%	$28.32	$12.04 ▼ $31.44	$1.94B	1.27	173,673 shs	132,821 shs
SPRY ARS Pharmaceuticals	$4.11 -1.0%	$5.78	$4.10 ▼ $13.15	$408.73M	1.05	1.44 million shs	1.89 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	0.00%	+8.48%	-1.53%	-4.21%	-20.16%
ETON Eton Pharmaceuticals	0.00%	-2.77%	-7.36%	+70.87%	+213.91%
GHRS GH Research	0.00%	+3.90%	-1.46%	+27.07%	+126.08%
SPRY ARS Pharmaceuticals	0.00%	-13.66%	-25.41%	-57.41%	-57.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	2.50	Moderate Buy	$103.00	35.28% Upside
ETON Eton Pharmaceuticals	2.50	Moderate Buy	$67.50	21.62% Upside
GHRS GH Research	2.75	Moderate Buy	$45.00	59.24% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$26.40	542.34% Upside

Current Analyst Ratings Breakdown

Latest SPRY, GHRS, ETON, and ANIP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	ANIP ANI Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$104.00
9/8/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/24/2026	ETON Eton Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	ETON Eton Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $68.00
8/14/2026	ETON Eton Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $70.00
8/14/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $70.00
8/13/2026	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	ANIP ANI Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/11/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$57.00 ➝ $65.00
8/10/2026	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$124.00 ➝ $119.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$883.37M	1.98	$9.94 per share	7.66	$24.03 per share	3.17
ETON Eton Pharmaceuticals	$79.95M	19.84	$0.01 per share	10,707.67	$0.98 per share	56.63
GHRS GH Research	N/A	N/A	N/A	N/A	$4.51 per share	N/A
SPRY ARS Pharmaceuticals	$84.28M	4.85	N/A	N/A	$1.16 per share	3.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$78.34M	$4.64	16.41	8.85	N/A	11.07%	27.37%	10.47%	11/6/2026 (Estimated)
ETON Eton Pharmaceuticals	-$4.60M	$0.38	146.05	28.61	N/A	12.02%	40.13%	12.37%	11/5/2026 (Estimated)
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.86%	-20.12%	11/5/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest SPRY, GHRS, ETON, and ANIP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ETON Eton Pharmaceuticals	$0.1898	$0.43	+$0.2402	$0.35	$27.11 million	$37.59 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	$2.21	+$0.17	$1.05	$260.13 million	$266.04 million
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	0.99	2.91	2.41
ETON Eton Pharmaceuticals	0.41	1.52	1.30
GHRS GH Research	N/A	28.70	28.70
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
ETON Eton Pharmaceuticals	27.86%
GHRS GH Research	56.90%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	8.10%
ETON Eton Pharmaceuticals	16.49%
GHRS GH Research	41.60%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	970	22.97 million	21.11 million	Optionable
ETON Eton Pharmaceuticals	44	28.58 million	23.87 million	Optionable
GHRS GH Research	73	68.61 million	40.07 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable

SPRY, GHRS, ETON, and ANIP Headlines

Recent News About These Companies

ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

September 18 at 8:32 PM | globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

September 18 at 9:23 AM | globenewswire.com

SPRY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

September 18 at 8:55 AM | newsfilecorp.comN

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026

September 18 at 8:15 AM | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 17 at 12:00 PM | globenewswire.com

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

September 17 at 10:07 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

September 17 at 10:00 AM | prnewswire.com

SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

September 16, 2026 | prnewswire.com

Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026

September 16, 2026 | newsfilecorp.comN

Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026

September 16, 2026 | newsfilecorp.comN

SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline

September 16, 2026 | prnewswire.com

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

September 16, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY